We are live on ! Find out more
DBG

De Burlo Group Portfolio holdings

AUM $441M
1-Year Est. Return 21.21%
This Fund
S&P 500
This Quarter Est. Return
-7.59%
1 Year Est. Return
+21.21%
3 Year Est. Return
+98.05%
5 Year Est. Return
+220.33%
10 Year Est. Return
+1,846.98%
AUM
$351M
AUM Growth
-$186M
Cap. Flow
-$133M
Cap. Flow %
-37.85%
Top 10 Hldgs %
76.44%
Holding
207
New
37
Increased
22
Reduced
25
Closed
123

Top Buys

Rank Stock Value
1
PG icon
Procter & Gamble
PG
+$35.7M
2
MCK icon
McKesson
MCK
+$33M
3
ELV icon
Elevance Health
ELV
+$28.2M
4
EOG icon
EOG Resources
EOG
+$26.4M
5
NVO
Novo Nordisk
NVO
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 28.18%
2 Consumer Staples 20.19%
3 Technology 15.79%
4 Energy 12.08%
5 Financials 8.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
YUMC icon
201
Yum China
YUMC
$14.9B
-672
Closed -$27.9K
ZTS icon
202
Zoetis
ZTS
$31.7B
-800
Closed -$151K
SRCL
203
DELISTED
Stericycle Inc
SRCL
-2,284
Closed -$135K
FRC
204
DELISTED
First Republic Bank
FRC
-100
Closed -$16.2K
CNCE
205
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
-200
Closed -$674
SPNE
206
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
-1,533
Closed -$18.6K
CERN
207
DELISTED
Cerner Corp
CERN
-500
Closed -$46.8K

Similar funds

De Burlo Group's Q2 2022 Portfolio in Review

As of Q2 2022, De Burlo Group held 207 positions worth $351M, down 35% from $537M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

De Burlo Group withdrew a net $133M in Q2 2022, closing 123 positions and reducing 25 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 19% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, De Burlo Group opened a new position in McKesson worth $33.7M.

  • De Burlo Group's largest Q2 2022 buy was McKesson: 103,170 shares worth $33.7M.
  • De Burlo Group added most to Procter & Gamble in Q2 2022, an estimated $35.7M increase.
  • De Burlo Group's biggest Q2 2022 reduction was Microsoft, cutting an estimated $27.1M.
  • De Burlo Group fully exited Regeneron Pharmaceuticals in Q2 2022, selling an estimated $18.3M.
  • De Burlo Group's ten largest holdings make up 76% of its $351M portfolio in Q2 2022.
  • De Burlo Group opened 37 new positions and closed 123 in Q2 2022.
  • De Burlo Group's portfolio value fell 35% quarter-over-quarter to $351M.

Based on De Burlo Group's 13F filing for Q2 2022, filed 11 Aug 2022.